Navigation Links
Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
Date:3/31/2008

SAN DIEGO, March 31 /PRNewswire/ -- Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory disease, today announced the appointment of two additional members to its board of directors: Dennis M. Fenton, Ph.D. and Stephen W. Kaldor, Ph.D.

Dr. Fenton has 30 years of pharmaceutical and biotechnology experience, including over two decades at Amgen where he played an instrumental role in the development of the company into a global, fully-integrated, multi-billion dollar organization. Fenton's broad background includes executive leadership roles in manufacturing, process development, sales and marketing, operations and quality control. His most recent role at Amgen was as Executive Vice President of Operations.

Fenton holds a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.

"Dennis is a biotechnology pioneer," said chief executive officer, Bob Baltera. "His experience and insight from his years at Amgen will be extremely useful for Amira as we plan our future. In addition to Dennis, we are also very pleased that Steve Kaldor will join our board of directors. Steve's experience in successful start-up companies further deepens our pool of experience and knowledge and I'm sure he will serve as a great partner for us."

Dr. Kaldor is currently president and chief executive officer of Ambrx, a private biotechnology company focused on the development of next-generation, protein-based medicines. Prior to joining Ambrx, Kaldor served as president and chief scientific officer of Syrrx, a structure-based drug discovery company, which he led through its $270 million acquisition by Takeda in 2005. He also spent over twelve years in various research and development roles at Eli Lilly and is a co-inventor of Viracept(R), a marketed AIDS drug.

Kaldor holds a B.S. in Chemistry from Columbia University and a Ph.D. in Organic Chemistry from Harvard University.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease.

The company combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.

In February 2008, Amira Pharmaceuticals and GlaxoSmithKline entered a global agreement for Amira's FLAP inhibitor program. The deal follows positive phase 1 data from novel product candidate AM103 for the oral treatment of respiratory disease.

Amira has raised $40 million to date from investors including Novo A/S (Copenhagen, Denmark), Avalon Ventures (San Diego, CA), Prospect Ventures (Palo Alto, CA) and Versant Ventures (Menlo Park, CA). For more information, visit http://www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dennis Joyce Joins Executive and Board Search Firm Hodge / Niederer / Cariani / Lindsay
2. Bacchus Vascular Names Dennis Rosenberg as Vice President of Marketing
3. Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007
4. TIGroup Names Dennis M. Smith as Chief Financial Officer
5. Dr. Steve Liu, CEO of Ingenious Med, Joins Benchmarks Committee at SHM
6. Stevens chemists identify compounds to lure nutria, a rat-like pest ravaging Gulf Coast wetlands
7. Northwestern Memorial Hospitals Steven J. Stryker MD Unveils Campaign With Empower Public Relations
8. Stevens UV expert at Science-on-Saturday program
9. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse
10. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study
11. Play by Steve Nash, Assisted by Milk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man ... is the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at ... school and at 19 years of age, he joined the Navy and got married right ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study ... Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure ...
(Date:1/20/2017)... ... ... a beautiful and enchanting tale that teaches children the true meaning of Christmas. “Journey to ... City, and a devoted woman of faith. , “Becoming a parent changes you. In ... my mind for years, but actually doing it might have been a while in coming ...
(Date:1/20/2017)... ... , ... “The Land of More and More”: a brilliant story for ... shares the simple and achievable answer. “The Land of More and More” is the ... Church in Angola, Indiana where he works with the children’s ministry department. , ...
(Date:1/19/2017)... ... 20, 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) ... Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid for the ... of the Administration’s effort to build a system that delivers better care and one ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 20, 2017  Palladian Health, a leading provider ... launch of an opioid management program which assists ... and helps stem the growing tide of dependence ... treat chronic non-cancer pain (back pain, neck pain, ... lack of evidence regarding long-term effectiveness. ...
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... Ophthalmic Devices Market? Which areas are going to grow ... potential revenues to 2026, assessing data, trends, opportunities and ... and graphs. Discover the most lucrative areas in the ... lets you assess forecasted sales across the all the ...
Breaking Medicine Technology: